XML 24 R15.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Related Party Transactions | 9 Months Ended
--- | ---
Sep. 30, 2022
Related Party Transactions [Abstract] |
Related Party Transactions | 7. Related Party Transactions Astellas is an equity investor in the Company and is considered a related party. The Company recorded revenue related to collaboration agreements with Astellas of $1.4 million and $12 2.6 million for the three months ended September 30, 2022 and 2021, and $31.0 million and $128.8 million for the nine months ended September 30, 2022 and 2021, respectively. The Company also recorded drug product revenue from Astellas of $(4.1) million and zero for the three months ended September 30, 2022 and 2021, and $4.6 million and $2.1 million for the nine months ended September 30, 2022 and 2021, respectively. See Note 2, Collaboration Agreements, License Agreement and Revenues, for details. The Company’s expense related to collaboration agreements with Astellas was immaterial for each of the three and nine months ended September 30, 2022 and 2021. As of September 30, 2022 and December 31, 2021, accounts receivable from Astellas were $1.4 million and $10.9 million, respectively. As of September 30, 2022 and December 31, 2021, total deferred revenue from Astellas was $47.0 million and $27.9 million, respectively. As of September 30, 2022, the amount due to Astellas was $55.3 million. As of December 31, 2021, amount due to Astellas was immaterial. Falikang, an entity jointly owned by FibroGen Beijing and AstraZeneca is an unconsolidated VIE accounted for as an equity method investment, and considered as a related party to the Company. FibroGen Beijing owns 51.1% of Falikang’s equity. See Note 3, Variable Interest Entity, for details. The net product revenue from Falikang was $14.9 million and $10.3 million for the three months ended September 30, 2022 and 2021, and $50.9 million and $32.5 million for the nine months ended September 30, 2022 and 2021, respectively. See the Product Revenue, Net section in Note 2, Collaboration Agreements, License Agreement and Revenues, for details. The investment income in Falikang was $0.4 million and $0.3 million for the three months ended September 30, 2022 and 2021, and $1.3 million and $0.7 million for the nine months ended September 30, 2022 and 2021, respectively. As of September 30, 2022 and December 31, 2021, the Company’s equity method investment in Falikang was $4.6 million and $3.8 million, respectively. See Note 3, Variable Interest Entity, for details. As of September 30, 2022, accounts receivable, net, from Falikang was of $12.9 million. As of December 31, 2021, accounts receivable, net, from Falikang was zero. As of September 30, 2022, the total deferred revenue from Falikang was zero. As of December 31, 2021, the total deferred revenue from Falikang was $1.2 million.

X
- References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -URI https://asc.fasb.org/topic&trid=2122745 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864 + Details
Name: | us-gaap_RelatedPartyTransactionsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration